OBJECTIVE: To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997-2007). RESULTS: Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region's population). The total follow-up was 5,462 patients-years. Median age was 74 years. INR therapeutic range was 2.0-3.0 in 82.5%. Atrial fibrillation (AF) was the most frequent indication (73%). Incidence of hemorrhagic and thrombotic events was 2.27 and 0.2/100 patients-year, respectively. Gastrointestinal tract was the most frequent site of bleeding. In multivariate analysis, patients with AF and prosthetic heart valves (PHV) had increased risk of bleeding (OR 2.1 and 4.8, respectively). Age and therapeutic ranges of INR were not associated with increased risk of bleeding. CONCLUSIONS: 2% of our population is receiving acenocoumarol. Incidence of hemorrhagic and thrombotic events was low. Patients with AF and PHV had increased risk of bleeding.
OBJECTIVE: To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997-2007). RESULTS: Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region's population). The total follow-up was 5,462 patients-years. Median age was 74 years. INR therapeutic range was 2.0-3.0 in 82.5%. Atrial fibrillation (AF) was the most frequent indication (73%). Incidence of hemorrhagic and thrombotic events was 2.27 and 0.2/100 patients-year, respectively. Gastrointestinal tract was the most frequent site of bleeding. In multivariate analysis, patients with AF and prosthetic heart valves (PHV) had increased risk of bleeding (OR 2.1 and 4.8, respectively). Age and therapeutic ranges of INR were not associated with increased risk of bleeding. CONCLUSIONS: 2% of our population is receiving acenocoumarol. Incidence of hemorrhagic and thrombotic events was low. Patients with AF and PHV had increased risk of bleeding.
Authors: J Acar; B Iung; J P Boissel; M M Samama; P L Michel; J P Teppe; J C Pony; H L Breton; D Thomas; R Isnard; G de Gevigney; E Viguier; A Sfihi; G Hanania; M Ghannem; A Mirode; C Nemoz Journal: Circulation Date: 1996-11-01 Impact factor: 29.690
Authors: V Pengo; F Barbero; A Banzato; E Garelli; F Noventa; A Biasiolo; A Zasso; S Dalla Volta Journal: Thromb Haemost Date: 1997-05 Impact factor: 5.249
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Jonas Wallvik; Anders Själander; Lars Johansson; Orjan Bjuhr; Jan-Håkan Jansson Journal: Scand J Prim Health Care Date: 2007-06 Impact factor: 2.581
Authors: José L Navarro; Jesús M Cesar; María A Fernández; Jordi Fontcuberta; Joan C Reverter; Jordi Gol-Freixa Journal: Rev Esp Cardiol Date: 2007-12 Impact factor: 4.753
Authors: Johana Alejandra Moreno-Drada; Alex Junio Silva da Cruz; Matheus Luis Soares de Faria; Luís Otávio Miranda Cota; Maria Auxiliadora Parreiras Martins; Isabela Almeida Pordeus; Mauro Henrique Nogueira Guimarães de Abreu Journal: Int J Environ Res Public Health Date: 2021-04-02 Impact factor: 3.390